Is amlodipine (calcium channel blocker) a vasodilator?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amlodipine's Mechanism of Action as a Vasodilator

Yes, amlodipine is a potent peripheral and coronary vasodilator that acts directly on vascular smooth muscle to reduce peripheral vascular resistance and blood pressure. 1

Mechanism of Action

  • Amlodipine is a dihydropyridine calcium channel blocker (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle 1
  • It selectively inhibits calcium ion influx across cell membranes, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells 1
  • Amlodipine acts as a peripheral arterial vasodilator that directly affects vascular smooth muscle, causing reduction in peripheral vascular resistance 1
  • Among calcium channel blockers, nifedipine and amlodipine have the most pronounced peripheral arterial dilatory effects 2

Vasodilatory Properties

  • Amlodipine produces vasodilation resulting in a reduction of both supine and standing blood pressures following therapeutic dosing 1
  • It has high selectivity for vascular smooth muscle with potent vasodilatory effects and minimal impact on myocardial contractility or cardiac conduction 3
  • The vasodilatory action is responsible for the most common side effects associated with amlodipine therapy, including peripheral edema and flushing 4
  • Amlodipine blocks constriction and restores blood flow in coronary arteries and arterioles in response to various vasoconstrictive stimuli, making it effective for vasospastic angina 1

Pharmacodynamic Profile

  • Amlodipine has a gradual onset of effect due to its slow rate of association and dissociation with the calcium channel receptor binding site 1
  • It has a long duration of action with an elimination half-life of 36-45 hours, allowing for once-daily dosing 3, 5
  • The gradual onset of action results in less reflex tachycardia compared to other dihydropyridines, with chronic oral administration not leading to clinically significant changes in heart rate 1, 6
  • Amlodipine's antihypertensive effectiveness is maintained for at least 24 hours with once-daily dosing 1

Clinical Applications

  • Amlodipine's vasodilatory properties make it effective for treating hypertension, chronic stable angina, and vasospastic angina 3
  • For exertional angina, amlodipine reduces total peripheral resistance (afterload) and myocardial oxygen demand 1
  • For vasospastic angina, its inhibition of coronary spasm is responsible for its effectiveness 1
  • Amlodipine is well tolerated by patients with mild left ventricular dysfunction, unlike verapamil and diltiazem which should be avoided in patients with pulmonary edema or severe left ventricular dysfunction 2

Comparison to Other Calcium Channel Blockers

  • Calcium channel blockers are classified as dihydropyridines (like amlodipine) or non-dihydropyridines (like diltiazem and verapamil) 2
  • While all calcium channel blockers cause coronary vasodilation, they vary in their effects on peripheral vasodilation, myocardial contractility, and cardiac conduction 2
  • Amlodipine is considered more potent and longer-acting compared to newer calcium channel blockers 7
  • Unlike verapamil and diltiazem, which have prominent effects on AV node and sinus node, amlodipine has few or no AV or sinus node effects 2

Cautions and Considerations

  • Rapid-release, short-acting dihydropyridines (e.g., nifedipine) should be avoided without concomitant beta-blockade due to increased adverse potential 2
  • Calcium channel blockers, including amlodipine, do not improve survival in patients with chronic stable angina with or without myocardial infarction 2
  • In patients with erythromelalgia, calcium channel blockers may worsen symptoms, and discontinuation has resulted in symptom resolution in several patients 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Amlodipine: a new calcium antagonist.

American journal of hospital pharmacy, 1994

Research

An update on the safety of amlodipine.

Journal of cardiovascular pharmacology, 1991

Research

Amlodipine in the Era of New Generation Calcium Channel Blockers.

The Journal of the Association of Physicians of India, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.